Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
AstraZeneca (AZN.US) Relizumab's new indication is proposed for priority review

AstraZeneca (AZN.US) Relizumab's new indication is proposed for priority review

智通财经智通财经2026/10/12 23:11
Show original
According to Jin Zhi Finance APP, on October 12, the website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that a new indication of AstraZeneca (AZN.US) ravulizumab injection is proposed to be included in priority review, aiming to reduce proteinuria levels in adult patients with primary IgA nephropathy (IgAN). Ravulizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billion USD in 2025 (YOY +20.23%).
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Earnings Preview | The "buyer strike" in the tech sector is spreading; if Cisco (CSCO.US) guidance falls short of expectations, it could be yet another blow to tech stock sentiment

Cisco will release its financial report on November 12. The market expects EPS to increase by 33% year-on-year and revenue to reach $18.09 billion. The focus will be on AI orders and the integration with Splunk.

智通财经•2026/11/09 03:36